You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSelegiline
Accession NumberDB01037  (APRD00525)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. [PubChem]
Structure
Thumb
Synonyms
(−)-selegiline
L-Deprenalin
Selegilina
Selegilinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-selegilinetablet5 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Eldeprylcapsule5 mg/1oralMylan Specialty2012-07-02Not applicableUs
Eldepryl - 5mg Tabtablet5 mgoralDraxis Health Inc.1997-09-022004-09-23Canada
Eldepryl Tab 5mgtablet5 mgoralDeprenyl Research Ltd.1990-12-311997-07-10Canada
Emsampatch12 mg/24htransdermalMylan Specialty2006-02-27Not applicableUs
Emsampatch6 mg/24htransdermalMylan Specialty2006-02-27Not applicableUs
Emsampatch9 mg/24htransdermalMylan Specialty2006-02-27Not applicableUs
Med Selegilinetablet5 mgoralMedican Pharma Incorporated1999-06-302011-03-29Canada
Mylan-selegilinetablet5 mgoralMylan Pharmaceuticals Ulc1997-04-09Not applicableCanada
Nu-selegilinetablet5 mgoralNu Pharm Inc1997-05-282012-09-04Canada
PMS-selegilinetablet5 mgoralPharmascience Inc1998-06-04Not applicableCanada
Selegilinetablet5 mgoralPharmel Inc1998-09-03Not applicableCanada
Selegiline-5tablet5 mgoralPro Doc Limitee1998-03-252010-07-13Canada
Teva-selegilinetablet5 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Zelapartablet, orally disintegrating1.25 mg/1oralValeant Pharmaceuticals North America LLC2006-06-14Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-selegilinetablet5 mgoralApotex Inc1997-02-13Not applicableCanada
Selegiline Hydrochloridecapsule5 mg/1oralDAVA Pharmaceuticals, Inc.2006-11-04Not applicableUs
Selegiline Hydrochloridetablet5 mg/1oralMylan Pharmaceuticals Inc.2010-03-08Not applicableUs
Selegiline Hydrochloridetablet5 mg/1oralGolden State Medical Supply, Inc.2013-04-02Not applicableUs
Selegiline Hydrochloridecapsule5 mg/1oralCarilion Materials Management2006-11-04Not applicableUs
Selegiline Hydrochloridetablet5 mg/1oralLibertas Pharma, Inc.2014-05-24Not applicableUs
Selegiline Hydrochloridecapsule5 mg/1oralApotex Corp.1997-07-15Not applicableUs
Selegiline Hydrochloridecapsule5 mg/1oralA S Medication Solutions1997-07-15Not applicableUs
Selegiline Hydrochloridecapsule5 mg/1oralLake Erie Medical DBA Quality Care Products LLC1997-07-15Not applicableUs
Selegiline Hydrochloridetablet5 mg/1oralApotex Corp.1997-07-06Not applicableUs
Selegiline Hydrochloridecapsule5 mg/1oralGolden State Medical Supply, Inc.2006-11-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarbexNot Available
JumexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Selegiline Hydrochloride
14611-52-0
Thumb
  • InChI Key: IYETZZCWLLUHIJ-UTONKHPSSA-N
  • Monoisotopic Mass: 223.112777288
  • Average Mass: 223.742
DBSALT000260
Categories
UNII2K1V7GP655
CAS number14611-51-9
WeightAverage: 187.2808
Monoisotopic: 187.136099549
Chemical FormulaC13H17N
InChI KeyInChIKey=MEZLKOACVSPNER-UHFFFAOYSA-N
InChI
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
IUPAC Name
methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine
SMILES
CC(CC1=CC=CC=C1)N(C)CC#C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMonotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
PharmacodynamicsDopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO-B. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.
Mechanism of actionAlthough the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding> 99.5%
MetabolismNot Available
Route of eliminationNot Available
Half life1.2-2 hours
ClearanceNot Available
ToxicityLD50=63 mg/kg (rats, IV)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier+0.9809
Caco-2 permeable+0.8453
P-glycoprotein substrateNon-substrate0.543
P-glycoprotein inhibitor INon-inhibitor0.9632
P-glycoprotein inhibitor IINon-inhibitor0.9779
Renal organic cation transporterInhibitor0.5327
CYP450 2C9 substrateNon-substrate0.7993
CYP450 2D6 substrateSubstrate0.6987
CYP450 3A4 substrateNon-substrate0.5671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9341
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9285
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9285
Ames testNon AMES toxic0.889
CarcinogenicityNon-carcinogens0.6567
BiodegradationNot ready biodegradable0.9767
Rat acute toxicity2.9199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8869
hERG inhibition (predictor II)Non-inhibitor0.8269
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Capsuleoral5 mg/1
Patchtransdermal12 mg/24h
Patchtransdermal6 mg/24h
Patchtransdermal9 mg/24h
Tabletoral5 mg/1
Tablet, orally disintegratingoral1.25 mg/1
Prices
Unit descriptionCostUnit
Emsam 30 12 mg/24hr Patches Box627.1USD box
Emsam 30 6 mg/24hr Patches Box627.1USD box
Emsam 30 9 mg/24hr Patches Box627.1USD box
Selegiline hcl powder127.3USD g
Eldepryl 30 5 mg capsule Box89.55USD box
Emsam 12 mg/24 hours patch20.1USD patch
Emsam 6 mg/24 hours patch20.1USD patch
Emsam 9 mg/24 hours patch20.1USD patch
Zelapar 1.25 mg odt tablet8.33USD tablet
Selegiline HCl 5 mg capsule2.4USD capsule
Selegiline hcl 5 mg tablet2.1USD tablet
Apo-Selegiline 5 mg Tablet1.33USD tablet
Mylan-Selegiline 5 mg Tablet1.33USD tablet
Novo-Selegiline 5 mg Tablet1.33USD tablet
Nu-Selegiline 5 mg Tablet1.33USD tablet
Pms-Selegiline 5 mg Tablet1.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5648093 No1994-07-152014-07-15Us
US6423342 No1996-03-012016-03-01Us
US7070808 No1998-05-102018-05-10Us
US7150881 No1998-06-122018-06-12Us
US7638140 No1998-05-102018-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point141-142 °CNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0254 mg/mLALOGPS
logP3.08ALOGPS
logP2.85ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)8.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity61.35 m3·mol-1ChemAxon
Polarizability22.48 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Silvia Ott-Dembrowski, Richard Cyrus, Jorg Schmidt, Hans Waiblinger, “Preparation of selegiline.” U.S. Patent US5847216, issued March, 1962.

US5847216
General References
  1. Engberg G, Elebring T, Nissbrandt H: Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. [PubMed:1658311 ]
  2. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956 ]
  3. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926 ]
  4. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016 ]
  5. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  6. Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. [PubMed:18311418 ]
  7. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
External Links
ATC CodesN04BD01
AHFS Codes
  • 28:92.00
  • 92:00.00
PDB Entries
FDA labelDownload (189 KB)
MSDSDownload (73.9 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineSelegiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineSelegiline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AbirateroneThe serum concentration of Selegiline can be increased when it is combined with Abiraterone.
AcarboseSelegiline may increase the hypoglycemic activities of Acarbose.
AcebutololSelegiline may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Selegiline.
AcetophenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Selegiline.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Selegiline.
AlbiglutideSelegiline may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Selegiline.
AliskirenSelegiline may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Selegiline.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Selegiline.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Selegiline.
AlogliptinSelegiline may increase the hypoglycemic activities of Alogliptin.
AlprenololSelegiline may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Selegiline.
AmbrisentanSelegiline may increase the hypotensive activities of Ambrisentan.
AmineptineSelegiline may increase the serotonergic activities of Amineptine.
AmiodaroneThe metabolism of Selegiline can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Amisulpride.
AmitriptylineSelegiline may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Selegiline.
AmlodipineSelegiline may increase the hypotensive activities of Amlodipine.
AmoxapineSelegiline may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Selegiline.
AmperozideThe risk or severity of adverse effects can be increased when Selegiline is combined with Amperozide.
AmphetamineSelegiline may increase the hypertensive activities of Amphetamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Selegiline.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Selegiline.
ApraclonidineThe risk or severity of adverse effects can be increased when Selegiline is combined with Apraclonidine.
AprepitantThe serum concentration of Selegiline can be increased when it is combined with Aprepitant.
ArbutamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Selegiline.
ArmodafinilThe metabolism of Selegiline can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Selegiline.
AsenapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Asenapine.
AtazanavirThe metabolism of Selegiline can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Selegiline.
AtenololSelegiline may increase the hypotensive activities of Atenolol.
AtomoxetineSelegiline may increase the central neurotoxic activities of Atomoxetine.
AtomoxetineThe metabolism of Selegiline can be decreased when combined with Atomoxetine.
AtropineSelegiline may increase the hypertensive activities of Atropine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Selegiline.
AzaperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Azaperone.
AzithromycinThe metabolism of Selegiline can be decreased when combined with Azithromycin.
BambuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Bambuterol.
BenazeprilSelegiline may increase the hypotensive activities of Benazepril.
BendroflumethiazideSelegiline may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineSelegiline may increase the hypertensive activities of Benzphetamine.
BepridilSelegiline may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Selegiline.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Selegiline.
BetaxololSelegiline may increase the hypotensive activities of Betaxolol.
BethanidineSelegiline may increase the hypotensive activities of Bethanidine.
BexaroteneThe serum concentration of Selegiline can be decreased when it is combined with Bexarotene.
BezafibrateThe risk or severity of adverse effects can be increased when Selegiline is combined with Bezafibrate.
BifeprunoxThe risk or severity of adverse effects can be increased when Selegiline is combined with Bifeprunox.
BimatoprostSelegiline may increase the hypotensive activities of Bimatoprost.
BisoprololSelegiline may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Selegiline can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Selegiline.
BortezomibThe metabolism of Selegiline can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Selegiline can be decreased when it is combined with Bosentan.
BosentanSelegiline may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Selegiline.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Selegiline.
BretyliumSelegiline may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brimonidine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Selegiline.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Selegiline.
BupranololSelegiline may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Selegiline.
BupropionSelegiline may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Selegiline.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Selegiline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Selegiline.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Selegiline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Selegiline.
CaffeineThe metabolism of Selegiline can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Selegiline.
CanagliflozinSelegiline may increase the hypoglycemic activities of Canagliflozin.
CandesartanSelegiline may increase the hypotensive activities of Candesartan.
CandoxatrilSelegiline may increase the hypotensive activities of Candoxatril.
CapecitabineThe metabolism of Selegiline can be decreased when combined with Capecitabine.
CaptoprilSelegiline may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Selegiline.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Selegiline.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Selegiline.
CariprazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Cariprazine.
CarteololSelegiline may increase the hypotensive activities of Carteolol.
CarvedilolSelegiline may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Selegiline can be decreased when combined with Celecoxib.
CeliprololSelegiline may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Selegiline can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Selegiline.
ChloramphenicolThe metabolism of Selegiline can be decreased when combined with Chloramphenicol.
ChlorothiazideSelegiline may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineSelegiline may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorpromazine.
ChlorpropamideSelegiline may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorprothixene.
ChlorthalidoneSelegiline may increase the hypotensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Selegiline can be decreased when combined with Cholecalciferol.
CilazaprilSelegiline may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Selegiline.
CimetidineThe metabolism of Selegiline can be decreased when combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Selegiline.
CirazolineSelegiline may increase the hypertensive activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Selegiline.
CitalopramSelegiline may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Selegiline can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Selegiline can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Selegiline.
ClemastineSelegiline may increase the anticholinergic activities of Clemastine.
ClemastineThe metabolism of Selegiline can be decreased when combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Clenbuterol.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Selegiline.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Selegiline.
ClomipramineSelegiline may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Selegiline.
ClonidineSelegiline may increase the hypotensive activities of Clonidine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Selegiline.
ClopidogrelThe metabolism of Selegiline can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Selegiline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clozapine.
CobicistatThe metabolism of Selegiline can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Selegiline.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Selegiline.
ConivaptanThe serum concentration of Selegiline can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Selegiline.
CrizotinibThe metabolism of Selegiline can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Selegiline.
CryptenamineSelegiline may increase the hypotensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Cyamemazine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Selegiline.
CyclosporineThe metabolism of Selegiline can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Selegiline.
CyclothiazideSelegiline may increase the hypotensive activities of Cyclothiazide.
CyproheptadineSelegiline may increase the anticholinergic activities of Cyproheptadine.
Cyproterone acetateThe serum concentration of Selegiline can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Selegiline.
DabrafenibThe serum concentration of Selegiline can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Selegiline.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Selegiline.
DapagliflozinSelegiline may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Selegiline.
DapoxetineSelegiline may increase the serotonergic activities of Dapoxetine.
DarunavirThe metabolism of Selegiline can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Selegiline can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Selegiline.
DebrisoquinSelegiline may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Selegiline can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Selegiline can be decreased when combined with Delavirdine.
DeserpidineSelegiline may increase the hypotensive activities of Deserpidine.
DesipramineSelegiline may increase the serotonergic activities of Desipramine.
DesipramineThe metabolism of Selegiline can be decreased when combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Selegiline.
DesvenlafaxineSelegiline may increase the serotonergic activities of Desvenlafaxine.
DexamethasoneThe serum concentration of Selegiline can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Selegiline.
DexmethylphenidateSelegiline may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineSelegiline may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanSelegiline may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Selegiline.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Selegiline.
DiazoxideSelegiline may increase the hypotensive activities of Diazoxide.
DiethylpropionSelegiline may increase the hypertensive activities of Diethylpropion.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Selegiline.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Selegiline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Selegiline.
DihydroergotamineThe metabolism of Selegiline can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Selegiline.
DiltiazemSelegiline may increase the hypotensive activities of Diltiazem.
DiltiazemThe metabolism of Selegiline can be decreased when combined with Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Selegiline is combined with Dipivefrin.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Selegiline.
DisopyramideSelegiline may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Selegiline.
DolasetronDolasetron may increase the serotonergic activities of Selegiline.
DomperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Domperidone.
DorzolamideSelegiline may increase the hypotensive activities of Dorzolamide.
DosulepinSelegiline may increase the serotonergic activities of Dosulepin.
DoxapramSelegiline may increase the hypertensive activities of Doxapram.
DoxazosinSelegiline may increase the hypotensive activities of Doxazosin.
DoxepinSelegiline may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Selegiline.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Selegiline.
DoxorubicinThe metabolism of Selegiline can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Selegiline can be decreased when combined with Doxycycline.
DoxylamineSelegiline may increase the anticholinergic activities of Doxylamine.
DronedaroneThe metabolism of Selegiline can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.
DroxidopaThe risk or severity of adverse effects can be increased when Selegiline is combined with Droxidopa.
DulaglutideSelegiline may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Selegiline.
DuloxetineSelegiline may increase the serotonergic activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Selegiline.
EfavirenzThe serum concentration of Selegiline can be decreased when it is combined with Efavirenz.
EfonidipineSelegiline may increase the hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Selegiline.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Selegiline.
EmpagliflozinSelegiline may increase the hypoglycemic activities of Empagliflozin.
EnalaprilSelegiline may increase the hypotensive activities of Enalapril.
EnalaprilatSelegiline may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Selegiline.
EnzalutamideThe serum concentration of Selegiline can be decreased when it is combined with Enzalutamide.
EphedraThe risk or severity of adverse effects can be increased when Selegiline is combined with Ephedra.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Selegiline.
EpinephrineSelegiline may increase the hypertensive activities of Epinephrine.
EpoprostenolSelegiline may increase the hypotensive activities of Epoprostenol.
EprosartanSelegiline may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Selegiline.
ErgotamineSelegiline may increase the hypertensive activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Selegiline.
ErythromycinThe metabolism of Selegiline can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Selegiline.
EscitalopramSelegiline may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Selegiline.
Eslicarbazepine acetateThe serum concentration of Selegiline can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineSelegiline may increase the serotonergic activities of Esmirtazapine.
EsomeprazoleThe metabolism of Selegiline can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Selegiline.
EstriolThe serum concentration of Estriol can be increased when it is combined with Selegiline.
EstroneThe serum concentration of Estrone can be increased when it is combined with Selegiline.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Selegiline.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Selegiline.
EtoperidoneSelegiline may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Selegiline.
EtravirineThe serum concentration of Selegiline can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Selegiline.
ExenatideSelegiline may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Selegiline.
FelodipineSelegiline may increase the hypotensive activities of Felodipine.
FelodipineThe metabolism of Selegiline can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fencamfamine.
FenfluramineSelegiline may increase the serotonergic activities of Fenfluramine.
FenoldopamSelegiline may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Selegiline.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Selegiline.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Selegiline.
FloxuridineThe metabolism of Selegiline can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Selegiline can be decreased when combined with Fluconazole.
FluorouracilThe metabolism of Selegiline can be decreased when combined with Fluorouracil.
FluoxetineSelegiline may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Selegiline can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Selegiline.
FluvastatinThe metabolism of Selegiline can be decreased when combined with Fluvastatin.
FluvoxamineSelegiline may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Selegiline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Formoterol.
FosamprenavirThe metabolism of Selegiline can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Selegiline can be increased when it is combined with Fosaprepitant.
FosinoprilSelegiline may increase the hypotensive activities of Fosinopril.
FosphenytoinThe metabolism of Selegiline can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Selegiline.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Selegiline.
Fusidic AcidThe serum concentration of Selegiline can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Selegiline.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Selegiline.
GemfibrozilThe metabolism of Selegiline can be decreased when combined with Gemfibrozil.
GliclazideSelegiline may increase the hypoglycemic activities of Gliclazide.
GlimepirideSelegiline may increase the hypoglycemic activities of Glimepiride.
GlipizideSelegiline may increase the hypoglycemic activities of Glipizide.
GlyburideSelegiline may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Selegiline.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Selegiline.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Selegiline.
GuanabenzSelegiline may increase the hypotensive activities of Guanabenz.
GuanadrelSelegiline may increase the hypotensive activities of Guanadrel.
GuanethidineSelegiline may increase the hypotensive activities of Guanethidine.
GuanfacineSelegiline may increase the hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.
HexamethoniumSelegiline may increase the hypotensive activities of Hexamethonium.
HydralazineSelegiline may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideSelegiline may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Selegiline.
HydroflumethiazideSelegiline may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideSelegiline may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Selegiline.
IdelalisibThe serum concentration of Selegiline can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Iloperidone.
ImatinibThe metabolism of Selegiline can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Selegiline.
ImipramineSelegiline may increase the serotonergic activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Selegiline.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Selegiline.
IndalpineSelegiline may increase the serotonergic activities of Indalpine.
IndapamideSelegiline may increase the hypotensive activities of Indapamide.
IndenololSelegiline may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Selegiline.
IndinavirThe metabolism of Selegiline can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Selegiline.
IndoraminSelegiline may increase the hypotensive activities of Indoramin.
Insulin AspartSelegiline may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirSelegiline may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineSelegiline may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineSelegiline may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanSelegiline may increase the hypoglycemic activities of Insulin Human.
Insulin LisproSelegiline may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Selegiline may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IrbesartanSelegiline may increase the hypotensive activities of Irbesartan.
IrbesartanThe metabolism of Selegiline can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Selegiline.
IsavuconazoniumThe metabolism of Selegiline can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Selegiline is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Selegiline is combined with Isometheptene.
IsoniazidThe metabolism of Selegiline can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoprenaline.
IsradipineSelegiline may increase the hypotensive activities of Isradipine.
IsradipineThe metabolism of Selegiline can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Selegiline can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Selegiline can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Selegiline.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Selegiline.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Selegiline.
KetoconazoleThe metabolism of Selegiline can be decreased when combined with Ketoconazole.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Selegiline.
LabetalolSelegiline may increase the hypotensive activities of Labetalol.
LacidipineSelegiline may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Selegiline.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Selegiline.
LanreotideSelegiline may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Selegiline.
LapatinibThe metabolism of Selegiline can be decreased when combined with Lapatinib.
LatanoprostSelegiline may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Selegiline.
LeflunomideThe metabolism of Selegiline can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Selegiline.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Selegiline.
LercanidipineSelegiline may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Selegiline.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Selegiline.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Selegiline.
LevomilnacipranSelegiline may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Selegiline.
LevonordefrinSelegiline may increase the hypertensive activities of Levonordefrin.
LidocaineThe metabolism of Selegiline can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Selegiline.
LinezolidThe risk or severity of adverse effects can be increased when Selegiline is combined with Linezolid.
LiraglutideSelegiline may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineSelegiline may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilSelegiline may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Selegiline.
LithiumThe risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.
LofexidineSelegiline may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Selegiline.
LopinavirThe metabolism of Selegiline can be decreased when combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Selegiline is combined with Lorcaserin.
LosartanSelegiline may increase the hypotensive activities of Losartan.
LosartanThe metabolism of Selegiline can be decreased when combined with Losartan.
LovastatinThe metabolism of Selegiline can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Loxapine.
Lu AA21004Selegiline may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Selegiline can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Selegiline can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.
MacitentanSelegiline may increase the hypotensive activities of Macitentan.
ManidipineSelegiline may increase the hypotensive activities of Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Selegiline.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Selegiline.
MecamylamineSelegiline may increase the hypotensive activities of Mecamylamine.
MecaserminSelegiline may increase the hypoglycemic activities of Mecasermin.
MelperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Melperone.
MephentermineSelegiline may increase the hypertensive activities of Mephentermine.
MequitazineSelegiline may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mesoridazine.
MetaraminolSelegiline may increase the hypertensive activities of Metaraminol.
MetforminSelegiline may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Methadone.
MethamphetamineSelegiline may increase the hypertensive activities of Methamphetamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Selegiline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methotrimeprazine.
MethoxamineSelegiline may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Selegiline is combined with Methyldopa.
Methylene blueSelegiline may increase the serotonergic activities of Methylene blue.
MethylphenidateSelegiline may increase the hypertensive activities of Methylphenidate.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Selegiline.
MetipranololSelegiline may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.
MetolazoneSelegiline may increase the hypotensive activities of Metolazone.
MetoprololSelegiline may increase the hypotensive activities of Metoprolol.
MexiletineThe metabolism of Selegiline can be decreased when combined with Mexiletine.
MianserinSelegiline may increase the neurotoxic activities of Mianserin.
MibefradilSelegiline may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Selegiline.
MidodrineSelegiline may increase the hypertensive activities of Midodrine.
MifepristoneSelegiline may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Selegiline can be decreased when combined with Mifepristone.
MiglitolSelegiline may increase the hypoglycemic activities of Miglitol.
MilnacipranSelegiline may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Selegiline.
MinoxidilSelegiline may increase the hypotensive activities of Minoxidil.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Selegiline.
MirtazapineSelegiline may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Selegiline.
MitotaneThe serum concentration of Selegiline can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Selegiline.
MoclobemideThe risk or severity of adverse effects can be increased when Selegiline is combined with Moclobemide.
MoclobemideThe metabolism of Selegiline can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Selegiline can be decreased when it is combined with Modafinil.
MoexiprilSelegiline may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Selegiline is combined with Morphine.
MoxonidineSelegiline may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Selegiline.
NadololSelegiline may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Selegiline can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Selegiline.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Selegiline.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Selegiline.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Selegiline.
NateglinideSelegiline may increase the hypoglycemic activities of Nateglinide.
NebivololSelegiline may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Selegiline can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Selegiline.
NelfinavirThe metabolism of Selegiline can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Selegiline can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Selegiline can be decreased when combined with Nevirapine.
NicardipineSelegiline may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Selegiline can be decreased when combined with Nicardipine.
NicorandilSelegiline may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Selegiline can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Selegiline.
NiguldipineSelegiline may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Selegiline can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Selegiline.
NilvadipineSelegiline may increase the hypotensive activities of Nilvadipine.
NimodipineSelegiline may increase the hypotensive activities of Nimodipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Selegiline.
NisoldipineSelegiline may increase the hypotensive activities of Nisoldipine.
NitrendipineSelegiline may increase the hypotensive activities of Nitrendipine.
NitroprussideSelegiline may increase the hypotensive activities of Nitroprusside.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Selegiline.
NorepinephrineSelegiline may increase the hypertensive activities of Norepinephrine.
NortriptylineSelegiline may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Selegiline.
OctreotideSelegiline may increase the hypoglycemic activities of Octreotide.
OlanzapineSelegiline may increase the serotonergic activities of Olanzapine.
OlaparibThe metabolism of Selegiline can be decreased when combined with Olaparib.
OlmesartanSelegiline may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Olodaterol.
OmapatrilatSelegiline may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Selegiline.
OmeprazoleThe metabolism of Selegiline can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Selegiline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Selegiline.
OrciprenalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Orciprenaline.
OsanetantThe risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant.
OsimertinibThe serum concentration of Selegiline can be increased when it is combined with Osimertinib.
OxcarbazepineOxcarbazepine may increase the serotonergic activities of Selegiline.
OxprenololSelegiline may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Selegiline.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Selegiline.
PalbociclibThe serum concentration of Selegiline can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Selegiline.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Selegiline.
PantoprazoleThe metabolism of Selegiline can be decreased when combined with Pantoprazole.
PargylineSelegiline may increase the hypotensive activities of Pargyline.
ParoxetineSelegiline may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Selegiline can be decreased when combined with Paroxetine.
PasireotideSelegiline may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Selegiline.
Peginterferon alfa-2bThe serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.
PenbutololSelegiline may increase the hypotensive activities of Penbutolol.
PentamidineSelegiline may increase the hypoglycemic activities of Pentamidine.
PentobarbitalThe metabolism of Selegiline can be increased when combined with Pentobarbital.
PentoliniumSelegiline may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Selegiline.
PerindoprilSelegiline may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Selegiline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perphenazine.
PethidineSelegiline may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Selegiline.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Selegiline.
PhenobarbitalThe metabolism of Selegiline can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Selegiline.
PhenoxybenzamineSelegiline may increase the hypotensive activities of Phenoxybenzamine.
PhentermineSelegiline may increase the hypertensive activities of Phentermine.
PhentolamineSelegiline may increase the hypotensive activities of Phentolamine.
PhenylephrineSelegiline may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Phenylpropanolamine.
PhenytoinThe metabolism of Selegiline can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Selegiline.
PholcodinePholcodine may increase the serotonergic activities of Selegiline.
PimozideThe risk or severity of adverse effects can be increased when Selegiline is combined with Pimozide.
PinacidilSelegiline may increase the hypotensive activities of Pinacidil.
PindololSelegiline may increase the hypotensive activities of Pindolol.
PioglitazoneSelegiline may increase the hypoglycemic activities of Pioglitazone.
PioglitazoneThe metabolism of Selegiline can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Pirbuterol.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Selegiline.
PizotifenSelegiline may increase the anticholinergic activities of Pizotifen.
PolythiazideSelegiline may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Selegiline.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Selegiline.
PosaconazoleThe metabolism of Selegiline can be decreased when combined with Posaconazole.
PramlintideSelegiline may increase the hypoglycemic activities of Pramlintide.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Selegiline.
PrazosinSelegiline may increase the hypotensive activities of Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Selegiline.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Selegiline.
PrimidoneThe metabolism of Selegiline can be increased when combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Selegiline.
PromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promethazine.
PropericiazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Propericiazine.
PropranololSelegiline may increase the hypotensive activities of Propranolol.
ProtriptylineSelegiline may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Selegiline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Selegiline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Selegiline.
PyrimethamineThe metabolism of Selegiline can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Selegiline can be increased when it is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Quetiapine.
QuinaprilSelegiline may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Selegiline.
QuinineSelegiline may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Selegiline can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Selegiline can be decreased when combined with Rabeprazole.
RamiprilSelegiline may increase the hypotensive activities of Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Selegiline.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Selegiline.
RanolazineThe metabolism of Selegiline can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Rasagiline.
RemikirenSelegiline may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.
RepaglinideSelegiline may increase the hypoglycemic activities of Repaglinide.
RescinnamineSelegiline may increase the hypotensive activities of Rescinnamine.
ReserpineSelegiline may increase the hypotensive activities of Reserpine.
RifabutinThe metabolism of Selegiline can be increased when combined with Rifabutin.
RifampicinThe metabolism of Selegiline can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Selegiline.
RifapentineThe metabolism of Selegiline can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Selegiline.
RiociguatSelegiline may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Risperidone.
RitodrineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ritodrine.
RitonavirThe metabolism of Selegiline can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Selegiline.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Selegiline.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Selegiline.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Selegiline.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Selegiline.
RopiniroleThe metabolism of Selegiline can be decreased when combined with Ropinirole.
RosiglitazoneSelegiline may increase the hypoglycemic activities of Rosiglitazone.
RosiglitazoneThe metabolism of Selegiline can be decreased when combined with Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Selegiline.
SalmeterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Salmeterol.
SaprisartanSelegiline may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Selegiline can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Selegiline.
SaxagliptinSelegiline may increase the hypoglycemic activities of Saxagliptin.
SecobarbitalThe metabolism of Selegiline can be increased when combined with Secobarbital.
SelexipagSelegiline may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Sertindole.
SertralineSelegiline may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Selegiline can be decreased when combined with Sertraline.
SildenafilThe metabolism of Selegiline can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Selegiline.
SiltuximabThe serum concentration of Selegiline can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Selegiline can be increased when it is combined with Simeprevir.
SitagliptinSelegiline may increase the hypoglycemic activities of Sitagliptin.
SitaxentanSelegiline may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Selegiline.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Selegiline.
SorafenibThe metabolism of Selegiline can be decreased when combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Selegiline.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Selegiline.
SpiraprilSelegiline may increase the hypotensive activities of Spirapril.
St. John's WortThe serum concentration of Selegiline can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Selegiline can be increased when it is combined with Stiripentol.
SulfadiazineSelegiline may increase the hypoglycemic activities of Sulfadiazine.
SulfadiazineThe metabolism of Selegiline can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSelegiline may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Selegiline can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleSelegiline may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Selegiline can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Selegiline.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Selegiline.
SunitinibSelegiline may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Selegiline.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Selegiline.
TamoxifenThe metabolism of Selegiline can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Selegiline.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Selegiline.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Selegiline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Selegiline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Selegiline is combined with Tedizolid Phosphate.
TelaprevirThe metabolism of Selegiline can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Selegiline.
TelithromycinThe metabolism of Selegiline can be decreased when combined with Telithromycin.
TelmisartanSelegiline may increase the hypotensive activities of Telmisartan.
TemocaprilSelegiline may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Selegiline.
TenofovirThe metabolism of Selegiline can be decreased when combined with Tenofovir.
TerbutalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.
TeriflunomideThe serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.
TerlipressinSelegiline may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Selegiline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Selegiline.
TetryzolineSelegiline may increase the hypertensive activities of Tetryzoline.
TheophyllineThe metabolism of Selegiline can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Selegiline.
ThiotepaThe metabolism of Selegiline can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Selegiline.
TianeptineSelegiline may increase the serotonergic activities of Tianeptine.
TiboloneSelegiline may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Selegiline.
TicagrelorThe metabolism of Selegiline can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Selegiline can be decreased when combined with Ticlopidine.
TicrynafenSelegiline may increase the hypotensive activities of Ticrynafen.
TimololSelegiline may increase the hypotensive activities of Timolol.
TocilizumabThe serum concentration of Selegiline can be decreased when it is combined with Tocilizumab.
TolazamideSelegiline may increase the hypoglycemic activities of Tolazamide.
TolazolineSelegiline may increase the hypotensive activities of Tolazoline.
TolbutamideSelegiline may increase the hypoglycemic activities of Tolbutamide.
TolbutamideThe metabolism of Selegiline can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Selegiline.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Selegiline.
TopiramateThe metabolism of Selegiline can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Selegiline.
TorasemideSelegiline may increase the hypotensive activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Selegiline.
TramadolTramadol may increase the neuroexcitatory activities of Selegiline.
TramadolThe risk or severity of adverse effects can be increased when Selegiline is combined with Tramadol.
TrandolaprilSelegiline may increase the hypotensive activities of Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tranylcypromine.
TranylcypromineThe metabolism of Selegiline can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Selegiline.
TravoprostSelegiline may increase the hypotensive activities of Travoprost.
TrazodoneSelegiline may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Selegiline.
TreprostinilSelegiline may increase the hypotensive activities of Treprostinil.
TrichlormethiazideSelegiline may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Triflupromazine.
TrimazosinSelegiline may increase the hypotensive activities of Trimazosin.
TrimethaphanSelegiline may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Selegiline can be decreased when combined with Trimethoprim.
TrimipramineSelegiline may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Selegiline.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Selegiline.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Selegiline.
UnoprostoneSelegiline may increase the hypotensive activities of Unoprostone.
Valproic AcidThe metabolism of Selegiline can be decreased when combined with Valproic Acid.
ValsartanSelegiline may increase the hypotensive activities of Valsartan.
ValsartanThe metabolism of Selegiline can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Selegiline.
VemurafenibThe serum concentration of Selegiline can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Selegiline can be decreased when combined with Venlafaxine.
VenlafaxineSelegiline may increase the serotonergic activities of Venlafaxine.
VerapamilThe metabolism of Selegiline can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Selegiline.
VilanterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Vilanterol.
VilazodoneSelegiline may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Selegiline.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Selegiline.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Selegiline.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Selegiline.
VoriconazoleThe metabolism of Selegiline can be decreased when combined with Voriconazole.
VortioxetineSelegiline may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Selegiline.
XylometazolineSelegiline may increase the hypotensive activities of Xylometazoline.
ZafirlukastThe metabolism of Selegiline can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Selegiline.
ZimelidineSelegiline may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Ziprasidone.
ZiprasidoneThe metabolism of Selegiline can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Selegiline.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Selegiline.
ZotepineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.
Food Interactions
  • Food increases the oral bioavailability by 3-5 fold.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48. [PubMed:1794016 ]
  3. Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22. [PubMed:9673855 ]
  4. Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11. [PubMed:12199263 ]
  5. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956 ]
  6. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926 ]
  7. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016 ]
  8. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  9. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  10. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  11. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  12. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  2. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  3. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. [PubMed:18311418 ]
  2. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  3. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414 ]
  4. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  2. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 02:15